PELP1: Structure, biological function and clinical significance

被引:34
作者
Sareddy, Gangadhara Reddy [1 ]
Vadlamudi, Ratna K. [1 ]
机构
[1] Univ Texas Hlth Sci Ctr San Antonio, Dept Obstet & Gynecol, San Antonio, TX 78229 USA
基金
美国国家卫生研究院;
关键词
Nuclear receptor; Estrogen receptor; Transcriptional activation; Hormonal action; Signal transduction; Coregulator; PELP1; GLUTAMIC-ACID-RICH; RECEPTOR COACTIVATOR PELP1/MNAR; GROWTH-FACTOR REGULATION; ESTROGEN-RECEPTOR; BREAST-CANCER; ANDROGEN RECEPTOR; PROLINE-RICH; ONCOGENIC FUNCTIONS; PROGNOSTIC-SIGNIFICANCE; NONGENOMIC ACTIVITY;
D O I
10.1016/j.gene.2016.03.017
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Proline-, glutamic acid-, and leucine-rich protein 1 (PELP1) is a scaffolding protein that functions as a coregulator of several transcription factors and nuclear receptors. Notably, the PELP1 protein has a histone-binding domain, recognizes histone modifications and interacts with several chromatin-modifying complexes. PELP1 serves as a substrate of multitude of kinases, and phosphorylation regulates its functions in various complexes. Further, PELP1 plays essential roles in several pathways including hormonal signaling, cell cycle progression, ribosomal biogenesis, and the DNA damage response. PELP1 expression is upregulated in several cancers, its deregulation contributes to therapy resistance, and it is a prognostic biomarker for breast cancer survival. Recent evidence suggests that PELP1 represents a novel therapeutic target for many hormonal cancers. In this review, we summarized the emerging biological properties and functions of PELP1. (C) 2016 Elsevier B.V. All rights reserved.
引用
收藏
页码:128 / 134
页数:7
相关论文
共 50 条
  • [41] SETDB1 interactions with PELP1 contributes to breast cancer endocrine therapy resistance
    Liu, Zexuan
    Liu, Junhao
    Ebrahimi, Behnam
    Pratap, Uday P.
    He, Yi
    Altwegg, Kristin A.
    Tang, Weiwei
    Li, Xiaonan
    Lai, Zhao
    Chen, Yidong
    Shen, Liangfang
    Sareddy, Gangadhara R.
    Viswanadhapalli, Suryavathi
    Tekmal, Rajeshwar R.
    Rao, Manjeet K.
    Vadlamudi, Ratna K.
    BREAST CANCER RESEARCH, 2022, 24 (01)
  • [42] PELP1 inhibition by SMIP34 reduces endometrial cancer progression via attenuation of ribosomal biogenesis
    Yang, Xue
    Liu, Zexuan
    Tang, Weiwei
    Pratap, Uday P.
    Collier, Alexia B.
    Altwegg, Kristin A.
    Gopalam, Rahul
    Li, Xiaonan
    Yuan, Yaxia
    Zhou, Daohong
    Lai, Zhao
    Chen, Yidong
    Sareddy, Gangadhara R.
    Valente, Philip T.
    Kost, Edward R.
    Viswanadhapalli, Suryavathi
    Vadlamudi, Ratna K.
    MOLECULAR ONCOLOGY, 2024, 18 (09) : 2136 - 2156
  • [43] SETDB1 interactions with PELP1 contributes to breast cancer endocrine therapy resistance
    Zexuan Liu
    Junhao Liu
    Behnam Ebrahimi
    Uday P. Pratap
    Yi He
    Kristin A. Altwegg
    Weiwei Tang
    Xiaonan Li
    Zhao Lai
    Yidong Chen
    Liangfang Shen
    Gangadhara R. Sareddy
    Suryavathi Viswanadhapalli
    Rajeshwar R. Tekmal
    Manjeet K. Rao
    Ratna K. Vadlamudi
    Breast Cancer Research, 24
  • [44] The clinical significance and biological function of interferon regulatory factor 1 in cholangiocarcinoma
    Wan, Peiqi
    Zhang, Junhong
    Du, Qiang
    Geller, David A.
    BIOMEDICINE & PHARMACOTHERAPY, 2018, 97 : 771 - 777
  • [45] Clinical and biological significance of glucocorticoid receptor (GR) expression in breast cancer
    Abduljabbar, Rezvan
    Negm, Ola H.
    Lai, Chun-Fui
    Jerjees, Dena A.
    Al-Kaabi, Methaq
    Hamed, Mohamed R.
    Tighe, Patrick J.
    Buluwela, Lakjaya
    Mukherjee, Abhik
    Green, Andrew R.
    Ali, Simak
    Rakha, Emad A.
    Ellis, Ian O.
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 150 (02) : 335 - 346
  • [46] Targeting PELP1 oncogenic signaling in TNBC with the small molecule inhibitor SMIP34
    Altwegg, Kristin A.
    Pratap, Uday P.
    Liu, Zexuan
    Liu, Junhao
    Sanchez, John R.
    Yang, Xue
    Ebrahimi, Behnam
    Panneerdoss, Durga Meenakshi
    Li, Xiaonan
    Sareddy, Gangadhara R.
    Viswanadhapalli, Suryavathi
    Rao, Manjeet K.
    Vadlamudi, Ratna K.
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 200 (01) : 151 - 162
  • [47] Altered Expression of ESR1, ESR2, PELP1 and c-SRC Genes Is Associated with Ovarian Cancer Manifestation
    Englert-Golon, Monika
    Andrusiewicz, Miroslaw
    Zbikowska, Aleksandra
    Chmielewska, Malgorzata
    Sajdak, Stefan
    Kotwicka, Malgorzata
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (12)
  • [48] Novel role of PELP1 in regulating chemotherapy response in mutant p53-expressing triple negative breast cancer cells
    Krishnan, Samaya R.
    Nair, Binoj C.
    Sareddy, Gangadhara R.
    Roy, Sudipa Saha
    Natarajan, Mohan
    Suzuki, Takayoshi
    Peng, Yan
    Raj, Ganesh
    Vadlamudi, Ratna K.
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 150 (03) : 487 - 499
  • [49] The prognostic value of estrogen receptor beta and proline-, glutamic acid- and leucine-rich protein 1 (PELP1) expression in ovarian cancer
    Aust, Stefanie
    Horak, Peter
    Pils, Dietmar
    Pils, Sophie
    Grimm, Christoph
    Horvat, Reinhard
    Tong, Dan
    Schmid, Bernd
    Speiser, Paul
    Reinthaller, Alexander
    Polterauer, Stephan
    BMC CANCER, 2013, 13
  • [50] Role of Scaffold Protein Proline-, Glutamic Acid-, and Leucine-Rich Protein 1 (PELP1) in the Modulation of Adrenocortical Cancer Cell Growth
    De Luca, Arianna
    Avena, Paola
    Sirianni, Rosa
    Chimento, Adele
    Fallo, Francesco
    Pilon, Catia
    Casaburi, Ivan
    Pezzi, Vincenzo
    CELLS, 2017, 6 (04)